Theranostics
The Combination of a Therapeutic and a Diagnostic
Perspective Therapeutics' platform allows confirmation of tumor target expression and distribution prior to therapy
Perspective Therapeutics’ leading Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides that bind with high affinity to proteins overexpressed on cancer cells. Perspective Therapeutics is also developing complementary imaging diagnostics that utilize the same targeting peptides but incorporate the gamma-emitter Pb-203 into a radiopharmaceutical chemically identical to the therapeutic molecule.
With this theranostic approach, physicians can use imaging with therapy-identical radiopharmaceuticals prior to treatment to confirm tumor target expression, preview potential off-target drug distribution, and determine which patients may respond to therapy. This approach potentially improves patient selection, management, and outcomes when compared to other types of cancer treatment.
Chemically identical molecules are used for diagnosis and therapy
